Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. Jan. 8, 2019. Johnathan Lancaster.

Executive Summary

The UK's National Institute for Health and Care Excellence (NICE) added Myriad Genetics' EndoPredict test to its recommendations for breast-cancer treatment as new data show the long-term prognostic value of the EndoPredict test in guiding therapy for many of these patients. See what the firm's chief medical officer has to say about it here.

"Hopefully it will be a game-changing offering to the clinical market place and I'm highly optimistic that this is going to be incredibly well received and will be a source of improvements in outcomes for patients." Johnathan Lancaster, chief medical officer, Myriad Genetics

Click here for a free trial of Medtech Insight.

 

 

Advertisement

Related Content

Myriad Finishes Big Year With NICE Endorsement Of EndoPredict Breast Cancer Diagnostic

Topics

Advertisement
UsernamePublicRestriction

Register

MT124460

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel